Telodendrimer nanocarrier for co-delivery of paclitaxel and cisplatin: A synergistic combination nanotherapy for ovarian cancer treatment.

Cisplatin (CDDP) and paclitaxel (PTX) are two established chemotherapeutic drugs used in combination for the treatment of many cancers, including ovarian cancer. We have recently developed a three-layered linear-dendritic telodendrimer micelles (TM) by introducing carboxylic acid groups in the adjacent layer via "thio-ene" click chemistry for CDDP complexation and conjugating cholic acids via peptide chemistry in the interior layer of telodendrimer for PTX encapsulation. We hypothesize that the co-delivery of low dosage PTX with CDDP could act synergistically to increase the treatment efficacy and reduce their toxic side effects. This design allowed us to co-deliver PTX and CDDP at various drug ratios to ovarian cancer cells. The in vitro cellular assays revealed strongest synergism in anti-tumor effects when delivered at a 1:2 PTX/CDDP loading ratio. Using the SKOV-3 ovarian cancer xenograft mouse model, we demonstrate that our co-encapsulation approach resulted in an efficient tumor-targeted drug delivery, decreased cytotoxic effects and stronger anti-tumor effect, when compared with free drug combination or the single loading TM formulations.

[1]  R. Dedrick,et al.  Physiological pharmacokinetic parameters for cis-dichlorodiammineplatinum(II) (DDP) in the mouse , 1992, Journal of Pharmacokinetics and Biopharmaceutics.

[2]  A. Kabanov,et al.  Biodegradable hybrid polymer micelles for combination drug therapy in ovarian cancer. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[3]  A. Kozubík,et al.  Platinum(IV) complex with adamantylamine overcomes intrinsic resistance to cisplatin in ovarian cancer cells. , 2006, Gynecologic oncology.

[4]  X. Jing,et al.  A prodrug strategy to deliver cisplatin(IV) and paclitaxel in nanomicelles to improve efficacy and tolerance. , 2012, Biomaterials.

[5]  S. Kaye,et al.  New Strategies in the Treatment of Ovarian Cancer: Current Clinical Perspectives and Future Potential , 2013, Clinical Cancer Research.

[6]  M. Relling,et al.  Variability in human cytochrome P450 paclitaxel metabolism. , 1995, The Journal of pharmacology and experimental therapeutics.

[7]  B. Monk,et al.  Latest research and treatment of advanced-stage epithelial ovarian cancer , 2013, Nature Reviews Clinical Oncology.

[8]  Alexander V Kabanov,et al.  Nanocarriers for delivery of platinum anticancer drugs. , 2013, Advanced drug delivery reviews.

[9]  L. Peters,et al.  Sequence‐dependent antitumor activity of paclitaxel (taxol) and cisplatin in vivo , 1995, International journal of cancer.

[10]  Ting-Chao Chou,et al.  Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies , 2006, Pharmacological Reviews.

[11]  Alexander Jesacher,et al.  A new tool to ensure the fluorescent dye labeling stability of nanocarriers: a real challenge for fluorescence imaging. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[12]  Mark J. Ratain,et al.  Pharmacokinetic variability of anticancer agents , 2005, Nature Reviews Cancer.

[13]  E. Macewen,et al.  Preclinical trial of doxorubicin entrapped in sterically stabilized liposomes in dogs with spontaneously arising malignant tumors , 1997, Cancer Chemotherapy and Pharmacology.

[14]  A. Corti,et al.  Synergistic Antitumor Activity of Cisplatin, Paclitaxel, and Gemcitabine with Tumor Vasculature-Targeted Tumor Necrosis Factor-α , 2006, Clinical Cancer Research.

[15]  A. Gabizon.  Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of Chemotherapy , 2001, Cancer investigation.

[16]  Eric Pridgen,et al.  Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles , 2008, Molecular pharmaceutics.

[17]  E K Rowinsky,et al.  Sequences of taxol and cisplatin: a phase I and pharmacologic study. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Xuesi Chen,et al.  Anti-tumor efficacy of c(RGDfK)-decorated polypeptide-based micelles co-loaded with docetaxel and cisplatin. , 2014, Biomaterials.

[19]  Hiroshi Maeda,et al.  Early Phase Tumor Accumulation of Macromolecules: A Great Difference in Clearance Rate between Tumor and Normal Tissues , 1998, Japanese journal of cancer research : Gann.

[20]  Charles E. Hoyle,et al.  Thiol—Ene Click Chemistry , 2010 .

[21]  E. Kaiser,et al.  Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. , 1970, Analytical biochemistry.

[22]  M. Sawyer,et al.  Pharmacogenetics of paclitaxel metabolism. , 2007, Critical reviews in oncology/hematology.

[23]  X. Jing,et al.  Co-delivery of daunomycin and oxaliplatin by biodegradable polymers for safer and more efficacious combination therapy. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[24]  Robert Langer,et al.  Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy , 2010, Proceedings of the National Academy of Sciences.

[25]  H. Maeda.  The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. , 2001, Advances in enzyme regulation.

[26]  K. Lam,et al.  Synthesis of hydrophilic and flexible linkers for peptide derivatization in solid phase. , 2004, Bioorganic & medicinal chemistry letters.

[27]  Gaojian Chen,et al.  Thiol-yne and thiol-ene "click" chemistry as a tool for a variety of platinum drug delivery carriers, from statistical copolymers to crosslinked micelles. , 2011, Biomacromolecules.

[28]  Carsten Denkert,et al.  Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells. , 2009, Cancer research.

[29]  Kristina U Wensing,et al.  Saving ears and kidneys from cisplatin. , 2013, Anticancer research.

[30]  X. Jing,et al.  The use of polymeric platinum(IV) prodrugs to deliver multinuclear platinum(II) drugs with reduced systemic toxicity and enhanced antitumor efficacy. , 2012, Biomaterials.

[31]  Li Wang,et al.  A self-assembling nanoparticle for paclitaxel delivery in ovarian cancer. , 2009, Biomaterials.

[32]  Kit S Lam,et al.  Well-defined, size-tunable, multifunctional micelles for efficient paclitaxel delivery for cancer treatment. , 2010, Bioconjugate chemistry.

[33]  M. Citardi,et al.  Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents taxol and vincristine , 2005, Journal of Cancer Research and Clinical Oncology.

[34]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.

[35]  Jingyu Yang,et al.  Gambogic acid synergistically potentiates cisplatin-induced apoptosis in non-small-cell lung cancer through suppressing NF-κB and MAPK/HO-1 signalling , 2013, British Journal of Cancer.

[36]  S. Howell,et al.  Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro. , 1994, British Journal of Cancer.

[37]  Christopher N Bowman,et al.  Thiol-ene click chemistry. , 2010, Angewandte Chemie.

[38]  Yong Zhang,et al.  PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel , 2010, Comput. Methods Programs Biomed..